Editas Medicine Inc

EDIT

NASDAQ. Currency in USD

9.83 -0.42 ( -4.10% )

Real time prices: December 05

Market Cap.
675.94M
Beta (5Y monthly)
1.96
Price/Earnings
-
EPS (TTM)
-2.94
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
3.45M
1y Target Est.
46.75
Day's Range
9.80
-
10.28
52 Week's Range
9.59
-
32.37

Historical Summary

Performance
EPS growth
Share Buybacks

About Editas Medicine Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.editasmedicine.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
68.40M
Employees
264
Address
11 Hurley Street, Cambridge, MA, United States, 02141
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Latest news

Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound?
Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 3 days ago

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage...
By GlobeNewswire Inc. - 4 days ago

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase...
By Zacks Investment Research - 1 week ago

Here's Why Editas (EDIT) Looks Ripe for Bottom Fishing
Here's Why Editas (EDIT) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT),...
By Zacks Investment Research - 1 week ago

Where Will Editas Medicine Be in 1 Year?
Where Will Editas Medicine Be in 1 Year?

The company could continue lagging the market for a while.
By The Motley Fool - 2 weeks ago

Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment

Credit Suisse has downgraded Editas Medicine Inc (NASDAQ: EDIT) from Outperform to Neutral with a...
By Benzinga - 2 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022

Upgrades According to Summit Insights Group, the prior rating for Applied Materials Inc (NASDAQ:AMAT) was...
By Benzinga - 2 weeks ago

Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down
Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down

Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness...
By Zacks Investment Research - 2 weeks ago